Dietary Supplement for Myopia Control
ConditionMyopia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-13
SponsorThe Hong Kong Polytechnic University
About this trial
The purpose of this clinical trial is to investigate the changes in choroidal thickness and vasculature in myopic children following oral supplementation.
Eligibility criteria
Qualifiers
Age 8-13 years
Cycloplegic spherical equivalent refraction (SER) of -0.50 D to -5.00 D with astigmatism of 2.5 D or less and best-corrected visual acuity (BCVA) of 0.0 logarithm or more in either eye
Anisometropia of 1.50 D or less
Intraocular pressure of 10 mmHg to 21 mmHg in both eyes
Disqualifiers
Ocular abnormalities leading to visual impairment
Severe physiological and psychological diseases affecting follow-up
Receiving previous myopia control treatment including but not limited to atropine therapy and orthokeratology in the past 3 months
Use of any other dietary supplements containing DHA/EPA, Lutein, or Astaxanthin in the past 3 months
Trial design
Treatments tested in this trial
- Oral dietary supplement provided in a capsule format (3 active capsules/ per day)
- Oral dietary supplement provided in a capsule format (1 active capsule and 2 placebo capsules/per day)
- Placebo control (3 placebo capsules/per day)
Treatment groups
156 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov